Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical enterprise headquartered in Vancouver, Canada. The company specializes in the development of innovative bispecific antibody therapeutics for the treatment of cancer. Its proprietary Azymetric and EFECT platforms enable the engineering of multispecific therapeutic candidates targeting complex oncological indications. Principal revenue is currently earned through strategic pharmaceutical research partnerships, clinical development collaborations, and licensing agreements as its drug candidates advance through clinical trials. Zymeworks Inc is publicly listed on the New York Stock Exchange.
7 of the funds FundTelligence covers report a position in Zymeworks.
- Legal name
- ZYMEWORKS
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
- Exposure themes
- Cancer, Treatment, Women's Health
Funds holding Zymeworks
- BNP US Small Cap — BNP Paribas · 1.01 % (full portfolio disclosed, June 2026)
- DNB Fund Women's Health — DNB · 0.84 % (full portfolio disclosed, August 2026)
- BNP Health Care Innovators — BNP Paribas · 0.78 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.13 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)